



## Results from phase II, open-label study of anti-tumoral activity of first-line erlotinib in advanced/metastatic NSCLC patients with EGFR activating mutations, in Portugal: The MuTAR study

Dear Editor,

Non-small cell lung cancer (NSCLC) is the most common cause of cancer death worldwide, with low survival (6–12 months and overall 5-year survival 5–10%), mostly because it is usually diagnosed in advanced stages.<sup>1</sup>

In NSCLC, the most common epidermal growth factor receptor (EGFR) mutations are exon 19 and exon 21, highly associated with sensitivity to tyrosine kinase inhibitors (TKI).<sup>2</sup> EGFR mutations are more common in non-smokers, women, adenocarcinomas and Asians patients.<sup>1</sup> Erlotinib is an orally active and potent TKI<sup>3</sup> indicated for first-line and maintenance treatment of patients with locally advanced or metastatic NSCLC with EGFR activating mutations.

This study (NCT01260181) was a phase II, non-randomized, open-label study to evaluate the anti-tumoral activity of erlotinib in patients with locally advanced or metastatic NSCLC with EGFR activating mutations. It was designed to evaluate the efficacy of erlotinib first-line treatment—as a single daily oral dose of 150 mg, until disease progression or unacceptable toxicity, death or withdrawal of consent—evaluated by complete or partial objective response rate (ORR) in Portugal.

This event-driven study was set up in 9 hospitals from January 2011 (start of recruitment period) to September 2017 (last safety follow-up visit).

There were 216 patients screened, 30 were enrolled, positive for exon 19 (40.0%) and/or exon 21 mutations (60.0%). Twenty-nine (96.7%) completed the treatment. At the end one patient was alive.

Patients' mean age was  $66.3 \pm 9.21$  years, 80% were female. Most were non-smokers (76.7%) with 20 pack-year smoking history. Median disease duration was 1 month (0–32 months) and histology for 96.7% of patients was adenocarcinoma. TNM classification was mostly stage IV (1 patient stage IIIB). Fifty percent of patients had bone metastatic disease and 80% another metastasis location. Two hundred and sixteen comorbidities have been reported and all patients had at least one. At screening, all patients had ECOG performance status 0 (20.0%), 1 (66.7%) or 2 (13.3%).

Efficacy results showed an ORR of 63.3% (95% CI: 46.1%–80.6%), in intention-to-treat, and 75.0% (95% CI: 50.1%–99.5%), in *per-protocol* population. The stable disease was the best overall response for the anti-tumoral activity in 30.0% of patients and progressive disease was the best overall response in 3.3%. The best overall response is summarized in Table 1.

Median progression-free survival (PFS) was 10 months (95% CI: 7.8–15.8), and median overall survival was 20.8 months (95% CI: 14–31.2). The median duration of response was 10.4 months (95% CI: 8–15.8). For exon 19 patients, the median PFS was 14.4 months (95% CI: 4.2–41.8) and for exon 21 9.8 months (95% CI: 3.8–13.5).

**Table 1** Best overall response (RECIST v1.1 criteria) for the study populations.

ITT population	Total (n = 30)
Best overall response, n (%)	
Complete response	0
Partial response	19 (63.3%)
Stable disease	9 (30.0%)
Progressive disease	1 (3.3%)
Inevaluable	0
Not available/not accessed	1 (3.3%)
Total	30
Objective response rate, <sup>a</sup> n (%)	19 (63.3%), [46.1%, 80.6%]
95%CI	
PP population	Total (n = 12)
Best overall response, n (%)	
Complete response	0
Partial response	9 (75.0%)
Stable disease	3 (25.0%)
Progressive disease	0
Not evaluable	0
Not available/not accessed	0
Total	12
Objective response rate, <sup>a</sup> n (%)	9 (75.0%), [50.1%, 99.5%]
95%CI	

Note: For the 7 patients without information of overall response at the end of the study visit, best overall response was obtained according to the information from the study treatment visits available.

95%CI: 95% confidence interval; ITT: intention to treat; PP: per protocol.

<sup>a</sup> Objective response rate: patients with complete or partial response.

Safety profile was as expected, with 341 adverse events reported by 29 patients. The most common AEs were rash acneiform (63.3% of patients) and diarrhea (50.0%) (Table 2). From these, 49.0% were at least remotely related to treatment. More than 65% of AEs were recovered/resolved while more than one third were not recovered/not resolved, and 3 (0.9%) were fatal. There were 10 SAEs experienced by 8 patients (26.7%), 5 of them were at least remotely related to study drug (diarrhea, gastrointestinal disorders, pelvic infection, skin and subcutaneous tissue disorders and vascular disorders). One AE (interstitial lung disease) was of special interest.

There were 4 deaths in the study, one due to pneumonia (not related to the study drug), one due to intestinal perforation (possibly related to the study drug), one unexplained (not related to the study drug) and the other due to progressive disease. At the end of study 51.9% of the patients had a subsequent therapy for NSCLC.

In our study, erlotinib has shown results similar to other published clinical trials in first-line treatment.<sup>4,5</sup> In EURTAC study of first-line erlotinib versus standard IV chemotherapy, PFS was significantly longer in erlotinib-treated patients (10.4 months) than chemotherapy patients (5.1 months). Another phase-II study<sup>4</sup> in Caucasians reinforced erlotinib as a first-line treatment of choice, with median PFS of 11

**Table 2** Incidence of AEs and SAEs in the safety population.

	Total (n = 30)
Patients with at least 1 adverse event ( $\geq 20\%$ ), n (%)	29 (96.7%)
Rash acneiform	19 (63.3%)
Diarrhea	15 (50.0%)
Anorexia	8 (26.7%)
Rash maculo-papular	8 (26.7%)
Respiratory, thoracic and mediastinal disorders	8 (26.7%)
Fatigue	7 (23.3%)
Paronychia	7 (23.3%)
Skin and subcutaneous tissue disorders	7 (23.3%)
Upper respiratory infection	7 (23.3%)
Constipation	6 (20.0%)
Eye disorders	6 (20.0%)
Gastrointestinal disorders	6 (20.0%)
Patients with AEs with remote, possible or probable relationship with study drug ( $\geq 20\%$ ), n (%)	28 (93.3%)
Rash acneiform	18 (60.0%)
Diarrhea	15 (50.0%)
Maculopapular rash	8 (26.7%)
Paronychia	7 (23.3%)
Skin and subcutaneous tissue disorders - Other, specify	7 (23.3%)
Patients with at least one serious adverse event, n (%)	8 (26.7%)
Depression	1 (3.3%)
Diarrhea	1 (3.3%)
Fracture	1 (3.3%)
Gastrointestinal disorders	1 (3.3%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	1 (3.3%)
Pelvic infection	1 (3.3%)
Renal and urinary disorders	1 (3.3%)
Respiratory, thoracic and mediastinal disorders	1 (3.3%)
Skin and subcutaneous tissue disorders	1 (3.3%)
Vascular disorders	1 (3.3%)
Patients with SAEs with remote, possible or probable relationship with study drug, n (%)	4 (13.3%)
Diarrhea	1 (3.3%)
Gastrointestinal disorders - Other, specify	1 (3.3%)
Pelvic infection	1 (3.3%)
Skin and subcutaneous tissue disorders - Other, specify	1 (3.3%)
Vascular disorders - Other, specify	1 (3.3%)
Deaths	4

months, clinical benefit rate of 81% and median OS of 23 months, in line with our results.

In BELIEF study,<sup>6</sup> of erlotinib 150 mg/day + intravenous bevacizumab 15 mg/kg/21 days, PFS was 13.2 months. In another double-blind, phase 3 trial in untreated patients with advanced NSCLC, EGFR mutation-positive for exon 19/21, assigned to osimertinib 80 mg/day or standard EGFR-TKI (gefitinib 250 mg od/erlotinib 150 mg/day), median PFS was 10.2 months with standard EGFR-TKIs and 18.9 months with osimertinib, with similar safety profile. The first-line bevacizumab + erlotinib versus erlotinib alone (BEVERLY study) is still waiting for results.

Safety profile was according to previous published clinical trials,<sup>3,4,6,7</sup> with rash and diarrhea being the most commonly reported, at mild/moderate intensity.

In conclusion, erlotinib has shown to be effective and well tolerated in Portuguese NSCLC EGFR mutated patients, with

locally advanced or metastatic stages. Our findings support erlotinib to be considered as first-line therapy option for locally advanced or metastatic NSCLC with EGFR-activating mutation in Portugal.

### Authors contributions

Fernando Barata contributed to the conception and design of the study.

Fernando Barata, Henrique Queiroga, Encarnação Teixeira, Teresa Almodovar, Marta Soares, Barbara Parente, Juan Carlos Mellidez, Paula Alves contributed to acquisition of data.

Fernando Barata, Ana Antunes contributed to analysis and interpretation of data.

Fernando Barata, Ana Antunes contributed to drafting the article.

Fernando Barata, Henrique Queiroga, Encarnação Teixeira, Teresa Almodovar, Marta Soares, Barbara Parente, Juan Carlos Mellidez, Paula Alves, Ana Antunes contributed to revising the article critically for important intellectual content.

All the authors contributed to the final approval of the version to be submitted.

## Funding

This work was supported by Roche.

## Conflict of interests

The authors, F. Barata, H. Queiroga, E. Teixeira, T. Almodovar, M. Soares, B. Parente, J.C. Mellidez, P. Alves, declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

A. Antunes declares herself to be employee of Roche Farmacêutica Química which can be perceived an competing interest.

## Acknowledgments

Medical writing and editorial assistance were provided by Catarina Alves, Medical Writer at Eurotrials, Scientific Consultants (now part of CTI Clinical Trial & Consulting Services), funded by Roche. Statistical support was provided by Vera Vicente, Senior Statistician at Eurotrials, Scientific Consultants (now part of CTI Clinical Trial & Consulting Services) and funded by Roche.

## References

1. D'Addario G, Felip E, Group EGW. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. *Ann Oncol*. 2008;19 Suppl 2, ii39–40.
2. Peng M, Weng YM, Liu HL, Yang GF, Yao Y, Han G, et al. Clinical characteristics and survival outcomes for non-small-cell lung cancer patients with epidermal growth factor receptor double mutations. *Biomed Res Int*. 2018;2018:7181368.
3. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicen S, Szczésna A, Juhász E, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. *Lancet Oncol*. 2010;11(6):521–9.

4. De Greve J, Van Meerbeeck J, Vansteenkiste JF, Decoster L, Meert AP, Vuylsteke P, et al. Prospective evaluation of first-line erlotinib in advanced non-small cell lung cancer (NSCLC) carrying an activating EGFR mutation: a multicenter academic phase II STUDY in Caucasian patients (FIET). *PLoS One*. 2016;11(3):e0147599.
5. Zhou C, Wu Y-L, Chen G, Feng J, Liu X-Q, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. *Lancet Oncol*. 2011;12(8):735–42.
6. Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, et al. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. *Lancet Respir Med*. 2017;5(5):435–44.
7. Cicen S, Geater SL, Petrov P, Hotko Y, Hooper G, Xia F, et al. Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study). *Lung Cancer*. 2016;102:30–7.

F. Barata<sup>a</sup>, H. Queiroga<sup>b</sup>, E. Teixeira<sup>c</sup>, T. Almodovar<sup>d</sup>, M. Soares<sup>e</sup>, B. Parente<sup>f</sup>, J.C. Mellidez<sup>g</sup>, P. Alves<sup>c</sup>, A. Antunes<sup>h,\*</sup>

<sup>a</sup> Centro Hospitalar e Universitário de Coimbra, Portugal

<sup>b</sup> Centro Hospitalar São João, Porto, Portugal

<sup>c</sup> Centro Hospitalar Lisboa Norte, Lisboa, Portugal

<sup>d</sup> Instituto Português de Oncologia Francisco Gentil, Lisboa, Portugal

<sup>e</sup> Instituto Português de Oncologia Francisco Gentil, Porto, Portugal

<sup>f</sup> Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal

<sup>g</sup> Centro Hospitalar Baixo Vouga, Aveiro, Portugal

<sup>h</sup> Roche Farmacêutica Química, Portugal

\* Corresponding author.

E-mail address: [ana.antunes@roche.com](mailto:ana.antunes@roche.com) (A. Antunes).

6 November 2019

<https://doi.org/10.1016/j.pulmoe.2020.08.007>

2531-0437/ © 2020 Sociedade Portuguesa de Pneumologia.

Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Value of rebiopsy in advanced Epidermal Growth Factor Receptor mutated Non-Small Cell Lung Cancer: Real-world data



### Letter to the Editor

Acquisition of Epidermal Growth Factor Receptor (EGFR) mutation resistance (mainly T790M) to EGFR tyrosine kinase inhibitors (TKI) occurs in about half of Non-Small Cell Lung Cancer (NSCLC) patients treated with TKI.<sup>1</sup> Mutational status is important to guide therapy.<sup>2,3</sup> Pirker stated that while

tissue biopsy is currently the main source for molecular analyses, liquid biopsies will gain importance for diagnosis and disease monitoring in the future.<sup>4</sup> The aim of this study was to analyse the value of liquid and tissue rebiopsy for evaluation of EGFR mutational status in a real-world setting.<sup>5,6</sup>

We carried out a retrospective identification of patients tested for EGFR mutation at a Portuguese cancer center between January 2015 and October 2019. We collected clinical data from patients with advanced EGFR mutation NSCLC. Descriptive statistic was used to analyse patients' characteristics.

Of the 824 patients that were evaluated for EGFR mutation, 160 (19%) had EGFR-mutant NSCLC.